ASHP

ASHP
Share

ASHP

 •  September 28, 2015

FDA and Novo Nordisk on September 25 announced the approval of two products containing the long-acting human basal insulin analog insulin degludec to improve blood glucose control in adults with type 1 or 2 diabetes.Insulin degludec is a recombinant analog of human insulin with one amino acid deletion and an added side chain consisting of glutamic ...

ASHP

 •  September 25, 2015

Denver—In 2010, the Institute for Safe Medication Practices (ISMP) declared the “syringe pull-back” method unsafe for preparing IV medications (ISMP Medication Safety Alert Acute Care 2010;15:13; http://goo.gl/​aM0SjO). Despite the imperative to move away from the practice, few institutions have taken additional safety measures such as ...

ASHP

 •  September 23, 2015

The American Society of Health-System Pharmacists (ASHP) will develop and implement national standardized concentrations for intravenous (IV) and oral liquid medications, thanks to a new FDA contract.The FDA awarded the three-year contract as part of its Safe Use Initiative, which facilitates public/ private partnerships to reduce preventable harm ...

ASHP

 •  September 23, 2015

FDA on Tuesday announced the approval of trifluridine–tipiracil tablets for the treatment of patients with metastatic colorectal cancer who have already undergone chemotherapy with fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens, a biological agent that binds to vascular endothelial growth factor, and, if appropriate, a drug that ...

ASHP

 •  September 22, 2015

The role of the health-system pharmacist in providing transitions-of-care services is expanding rapidly.

A survey of 1435 pharmacy directors employed at general and children’s medical-surgical hospitals across the United States showed that medication-use practices have improved significantly among health-system pharmacists since 2005.

Key ...

ASHP

 •  September 18, 2015

BETHESDA, MD 18 Sep 2015— FDA and Actavis on September 17 announced the approval of cariprazine oral capsules for the treatment of schizophrenia and acute manic or mixed episodes of bipolar disorder I in adults.The atypical antipsychotic is expected to be commercially available in the United States during the first quarter of 2016, according to an ...

ASHP

 •  September 17, 2015

Standardization Contract Is Part of FDA’s Safe Use Initiative
The Food and Drug Administration (FDA) has awarded ASHP a three-year contract to develop and implement national standardized concentrations for intravenous (IV) and oral liquid medications. The contract is part of FDA’s Safe Use Initiative, an effort to reduce preventable harm from ...

ASHP

 •  September 11, 2015

"Two-Midnight Rule" Clarification Coming in November
The Medicare program's shift from volume to value continues with the finalization of the regulation setting inpatient payment rates for fiscal year (FY) 2016, the Centers for Medicare and Medicaid Services (CMS) announced on July 31.The annual update to Medicare's inpatient prospective payment ...

ASHP

 •  September 10, 2015

A recombinant antihemophilic factor preparation produced in human cells has been licensed by FDA for use in patients with hemophilia A.The labeling (PDF) for the new recombinant product states that it is indicated for use in patients with hemophilia to provide "on-demand" treatment and control of bleeding episodes, perioperative management of ...

ASHP

 •  September 8, 2015

FDA on September 4 announced the approval of uridine triacetate oral granules as replacement therapy for patients with hereditary orotic aciduria (HOA), a rare metabolic disorder.Wellstat Therapeutics of Gaithersburg, Maryland, plans to market the therapy early next year under the brand name Xuriden.According to FDA, Xuriden is the only FDA ...